ARTICLE SUMMARY:
While first-generation companies offering new interventions for the ENT market modeled themselves after interventional cardiology, next-generation company Sinusys Corp. took its cue from the pharma industry. Its implant for the treatment of sinusitis is based on an osmotic drug delivery technology and it promises to be gentler, more comfortable for the patient, and perhaps more benign to tissue than first-generation procedures.
Companies that led the interventional revolution in the otolaryngology specialty, including Acclarent (now part of Johnson & Johnson), Entellus Medical Inc., and ENTrigue Surgical Inc.(part of Smith & Nephew PLC), did a great service for patients suffering from chronic sinusitis.
